BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 20444294)

  • 1. PKCalpha mediated induction of miR-101 in human hepatoma HepG2 cells.
    Chiang CW; Huang Y; Leong KW; Chen LC; Chen HC; Chen SJ; Chou CK
    J Biomed Sci; 2010 May; 17(1):35. PubMed ID: 20444294
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enhancer of zeste homolog 2 epigenetically silences multiple tumor suppressor microRNAs to promote liver cancer metastasis.
    Au SL; Wong CC; Lee JM; Fan DN; Tsang FH; Ng IO; Wong CM
    Hepatology; 2012 Aug; 56(2):622-31. PubMed ID: 22370893
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Protein kinase C alpha trigger Ras and Raf-independent MEK/ERK activation for TPA-induced growth inhibition of human hepatoma cell HepG2.
    Wen-Sheng W
    Cancer Lett; 2006 Jul; 239(1):27-35. PubMed ID: 16169661
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MicroRNA-26a suppresses epithelial-mesenchymal transition in human hepatocellular carcinoma by repressing enhancer of zeste homolog 2.
    Ma DN; Chai ZT; Zhu XD; Zhang N; Zhan DH; Ye BG; Wang CH; Qin CD; Zhao YM; Zhu WP; Cao MQ; Gao DM; Sun HC; Tang ZY
    J Hematol Oncol; 2016 Jan; 9():1. PubMed ID: 26733151
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MicroRNA-101 inhibits human hepatocellular carcinoma progression through EZH2 downregulation and increased cytostatic drug sensitivity.
    Xu L; Beckebaum S; Iacob S; Wu G; Kaiser GM; Radtke A; Liu C; Kabar I; Schmidt HH; Zhang X; Lu M; Cicinnati VR
    J Hepatol; 2014 Mar; 60(3):590-8. PubMed ID: 24211739
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reactive oxygen species-mediated PKC and integrin signaling promotes tumor progression of human hepatoma HepG2.
    Hu CT; Wu JR; Cheng CC; Wang S; Wang HT; Lee MC; Wang LJ; Pan SM; Chang TY; Wu WS
    Clin Exp Metastasis; 2011 Dec; 28(8):851-63. PubMed ID: 21842414
    [TBL] [Abstract][Full Text] [Related]  

  • 7. miR-26a promoted by interferon-alpha inhibits hepatocellular carcinoma proliferation and migration by blocking EZH2.
    Wang G; Sun Y; He Y; Ji C; Hu B; Sun Y
    Genet Test Mol Biomarkers; 2015 Jan; 19(1):30-6. PubMed ID: 25494962
    [TBL] [Abstract][Full Text] [Related]  

  • 8. EZH2 promotes hepatocellular carcinoma progression through modulating miR-22/galectin-9 axis.
    Chen S; Pu J; Bai J; Yin Y; Wu K; Wang J; Shuai X; Gao J; Tao K; Wang G; Li H
    J Exp Clin Cancer Res; 2018 Jan; 37(1):3. PubMed ID: 29316949
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activation of protein kinase C alpha is required for TPA-triggered ERK (MAPK) signaling and growth inhibition of human hepatoma cell HepG2.
    Wen-Sheng W; Jun-Ming H
    J Biomed Sci; 2005; 12(2):289-96. PubMed ID: 15917995
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Potential roles of EZH2, Bmi-1 and miR-203 in cell proliferation and invasion in hepatocellular carcinoma cell line Hep3B.
    Yang F; Lv LZ; Cai QC; Jiang Y
    World J Gastroenterol; 2015 Dec; 21(47):13268-76. PubMed ID: 26715809
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MicroRNA-21 promotes hepatocellular carcinoma HepG2 cell proliferation through repression of mitogen-activated protein kinase-kinase 3.
    Xu G; Zhang Y; Wei J; Jia W; Ge Z; Zhang Z; Liu X
    BMC Cancer; 2013 Oct; 13():469. PubMed ID: 24112539
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Overexpression of microRNA-30a-5p inhibits liver cancer cell proliferation and induces apoptosis by targeting MTDH/PTEN/AKT pathway.
    Li WF; Dai H; Ou Q; Zuo GQ; Liu CA
    Tumour Biol; 2016 May; 37(5):5885-95. PubMed ID: 26589417
    [TBL] [Abstract][Full Text] [Related]  

  • 13. EZH2-mediated concordant repression of Wnt antagonists promotes β-catenin-dependent hepatocarcinogenesis.
    Cheng AS; Lau SS; Chen Y; Kondo Y; Li MS; Feng H; Ching AK; Cheung KF; Wong HK; Tong JH; Jin H; Choy KW; Yu J; To KF; Wong N; Huang TH; Sung JJ
    Cancer Res; 2011 Jun; 71(11):4028-39. PubMed ID: 21512140
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MicroRNA-101 exerts tumor-suppressive functions in non-small cell lung cancer through directly targeting enhancer of zeste homolog 2.
    Zhang JG; Guo JF; Liu DL; Liu Q; Wang JJ
    J Thorac Oncol; 2011 Apr; 6(4):671-8. PubMed ID: 21270667
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Yin Yang 1-mediated epigenetic silencing of tumour-suppressive microRNAs activates nuclear factor-κB in hepatocellular carcinoma.
    Tsang DP; Wu WK; Kang W; Lee YY; Wu F; Yu Z; Xiong L; Chan AW; Tong JH; Yang W; Li MS; Lau SS; Li X; Lee SD; Yang Y; Lai PB; Yu DY; Xu G; Lo KW; Chan MT; Wang H; Lee TL; Yu J; Wong N; Yip KY; To KF; Cheng AS
    J Pathol; 2016 Apr; 238(5):651-64. PubMed ID: 26800240
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MiR-138 inhibits tumor growth through repression of EZH2 in non-small cell lung cancer.
    Zhang H; Zhang H; Zhao M; Lv Z; Zhang X; Qin X; Wang H; Wang S; Su J; Lv X; Liu H; Du W; Zhou W; Chen X; Fei K
    Cell Physiol Biochem; 2013; 31(1):56-65. PubMed ID: 23343715
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The putative tumour suppressor microRNA-124 modulates hepatocellular carcinoma cell aggressiveness by repressing ROCK2 and EZH2.
    Zheng F; Liao YJ; Cai MY; Liu YH; Liu TH; Chen SP; Bian XW; Guan XY; Lin MC; Zeng YX; Kung HF; Xie D
    Gut; 2012 Feb; 61(2):278-89. PubMed ID: 21672940
    [TBL] [Abstract][Full Text] [Related]  

  • 18. miR-98 inhibits hepatocellular carcinoma cell proliferation via targeting EZH2 and suppressing Wnt/β-catenin signaling pathway.
    Zhang JJ; Chen JT; Hua L; Yao KH; Wang CY
    Biomed Pharmacother; 2017 Jan; 85():472-478. PubMed ID: 27890434
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reciprocal negative feedback loop between EZH2 and miR-101-1 contributes to miR-101 deregulation in hepatocellular carcinoma.
    Huang D; Wang X; Zhuang C; Shi W; Liu M; Tu Q; Zhang D; Hu L
    Oncol Rep; 2016 Feb; 35(2):1083-90. PubMed ID: 26718325
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MicroRNA-30a suppresses tumor progression by blocking Ras/Raf/MEK/ERK signaling pathway in hepatocellular carcinoma.
    Zhou K; Luo X; Wang Y; Cao D; Sun G
    Biomed Pharmacother; 2017 Sep; 93():1025-1032. PubMed ID: 28732393
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.